Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alemtuzumab Consolidation in PTCL
NCT01806337Phase 2Completed
- Sponsor
- Georg-August-Universität Göttingen
- Start
- Jul 2003
- Primary completion
- Jul 2006
- Modality
- Monoclonal Antibodies
01
Overview
Phase 2, open-label, single-arm trial of alemtuzumab in peripheral T-cell lymphoma (PTCL), sponsored by Georg-August-Universität Göttingen. Primary endpoint: Feasibility of alemtuzumab consolidation at 24 weeks. Started Jul 2003; status: completed.
02
Drugs
alemtuzumab
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT01806337.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01806337.